MedTrace Logo

Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation

NCT02145546 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2014-05-23

No results posted yet for this study

Summary

The current evidences indicate that \~30% patients with sick sinus syndrome(SSS) would develop persistent atrial fibrillation (AF) after a long term pacing therapy. However, the accurate influence of antiarrhythmic drugs on the AF is still not well defined. The purpose of the study is to assess the therapeutic effects of various antiarrhythmic drugs (Amiodarone, Sotalol and Propafenone) on the long term management of AF in SSS patients with AF, including the reduced AF burden (duration and episodes) and persistent AF free survival rate. All patients will be followed up for 12 months.

Conditions

Interventions

DRUG

Amiodarone

Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.

DRUG

Propafenone

150mg per 8 hours, 3 times per day

DRUG

Sotalol

80mg twice per day.

Sponsors & Collaborators

  • Medtronic (Shanghai) Management Co. Ltd.

    collaborator INDUSTRY

  • Beijing CTSmed Co. Ltd

    collaborator UNKNOWN

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Yi-Gang Li, MD · Xinhua Hospital, Shanghai Jiaotong University School of Medicne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02145546 on ClinicalTrials.gov